research use only

Exatecan Mesylate Topoisomerase inhibitor

Cat.No.S8999

Exatecan Mesylate (DX-8951f) is a water-soluble and non-pro-drug analog of camptothecin and shows significant topoisomerase I inhibition with IC50 of 0.975 μg/ml.
Jump to

Quality Control

Batch: Purity: 99.97%
99.97

Solubility

In vitro
Batch:

DMSO : 12.5 mg/mL (23.51 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 12.5 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 531.55 Formula

C24H22FN3O4.CH4O3S

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 169869-90-3 -- Storage of Stock Solutions

Synonyms DX-8951 Mesylate SMILES CCC1(O)C(=O)OCC2=C1C=C3N(CC4=C5C(N)CCC6=C5C(=CC(=C6C)F)N=C34)C2=O.C[S](O)(=O)=O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
topoisomerase I
In vitro

Exatecan Mesylate shows both high potency against a series of 32 malignant cell lines and significant topoisomerase I inhibition in vitro. The anti‐proliferative activity of this compound is about 6 and 28 times greater than that of SN‐38 or SK&F 10486‐A, respectively.

In vivo

In mice, the antitumor activity of three doses of Exatecan Mesylate administered i.v. at 4‐day intervals against human gastric adenocarcinoma SC‐6 xenografts is greater than that of CPT‐11 or SK&F 10486‐A. Moreover, this compound overcame P‐glycoprotein‐mediated multi‐drug resistance. These data suggest that it has a high antitumor activity and is a potential therapeutic agent.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-02)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07454642 RECRUITING
Vulvar Adenocarcinoma; PDAC - Pancreatic Ductal Adenocarcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Small Cell Carcinoma of Lung; Colorectal Cancer; Hormone Receptor Positive Breast Carcinoma
Avacta Life Sciences Ltd
2026-03-31 PHASE1
NCT07360314 RECRUITING
Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
2026-02-13 PHASE1
NCT06730100 WITHDRAWN
Metastatic Mismatch Repair Proficient Colorectal Carcinoma; Refractory Mismatch Repair Proficient Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8
National Cancer Institute (NCI)
2026-02-17 PHASE2
NCT05691517 RECRUITING
Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)
2024-06-12 PHASE1
NCT00055939 COMPLETED
Sarcoma
Daiichi Sankyo
2003-01 PHASE2
NCT00055952 COMPLETED
Sarcoma
Daiichi Sankyo
2003-01 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map